Advanced Search
Contact | Corporate | Help

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

Sponsors:
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Genentech
Phases:
  • Phase I
IndicationsAcronym:
  • HIV Infections
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: CD4-IgG
Enrollment:
60

Additional information about NCT00000675.


SourceSolution © 2008-2012